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The use of physiologically based pharmacokinetic (PBPK) models has been proposed as a means of estimating the dose of the reactive metabolites
of carcinogenic xenobiotics reaching target tissues, thereby affording an opportunity to base estimates of potential cancer risk on tissue dose rather
than external levels of exposure. In this article, we demonstrate how a PBPK model can be constructed by specifying mass-balance equations for
each physiological compartment included in the model. In general, this leads to a system of nonlinear partial differential equations with which to
characterize the compartmental system. These equations then can be solved numerically to determine the concentration of metabolites in each
compartment as functions of time. In the special case of a linear pharmacokinetic system, we present simple closed-form expressions for the area
under the concentration-time curves (AUC) in individual tissue compartments. A general relationship between the AUC in blood and other tissue
compartments is also established. These results are of use in identifying those parameters in the models that characterize the integrated tissue
dose, and which should therefore be the primary focus of sensitivity analyses. Applications of PBPK modeling for purposes of tissue dosimetry are
reviewed, including models developed for methylene chloride, ethylene oxide, 1,4-dioxane, 1-nitropyrene, as well as polychlorinated biphenyls, diox-
ins, and furans. Special considerations in PBPK modeling related to aging, topical absorption, pregnancy, and mixed exposures are discussed. The
linkage between pharmacokinetic models used for tissue dosimetry and pharmacodynamic models for neoplastic transformation of stem cells in
the target tissue is explored. Environ Health Perspect 102(Suppl 1 1):37-50 (1994)
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Introduction
Pharmacokinetics is the study of the
absorption, distribution, metabolism, and
elimination ofxenobiotic agents in biologic
systems. By studying the fate ofxenobiotics
upon entering the body, it is possible to
obtain information on the amount ofboth
the parent compound and reactive metabo-
lites reaching tissues that may be targets'for
the induction of cancerous lesions. This
affords an opportunity to incorporate data
on tissue dose into pharmacodynamic
models ofcarcinogenesis.
Considerable experience has now accumu-
lated with the development ofphysiologically
based pharmacokinetic (PBPK) models to
describe the disposition ofcarcinogenic xeno-
biotics. Each compartment in a PBPK model
represents a physiologically defined compo-
nent ofthe body, such as blood or specific
organs and tissues. Physiologic parameters
such as bodyweight, blood flow rates, and tis-
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suevolumes are used to characterize the distri-
bution ofxenobiotics within the structure
provided by the PBPK model; biochemical
parameters such as partition coefficients gov-
ern uptake within target tissues. Metabolism
in the liver or other tissues is generally
described by first-order or Michaelis-Menten
kinetics. PBPK models capable ofaccurately
describing chemical disposition within mam-
malian systems havebeendeveloped foratleast
15 chemical substances (1).
Traditional methods for predicting
potential carcinogenic risk in humans from
animal data involve a number ofempirical
assumptions (2). First, for low levels of
exposure, it is generally assumed that car-
cinogenic risk is directly proportional to the
level ofexposure. Second, it is assumed that
humans are at least as sensitive as the most
sensitive animal species. In addition, inter-
species scaling of carcinogenic potency is
done in relation to body surface area or
body weight, or an intermediate scaling fac-
tor (3,4). And third, it is tacitly assumed
that the dose of the proximate carcinogen
reaching the target tissue is proportional to
the level of exposure to the parent com-
pound. It should be noted, however, that
classic pharmacokinetic and biochemical
studies have indicated that some metabolic
pathways are saturable, even at low levels of
exposure. This phenomenon could give rise
to a nonlinear dose-response relationship
with a biochemical threshold.
The comparatively recent application of
PBPK modeling to predict the dose of the
proximate carcinogen delivered to the tar-
get tissue obviates the need to rely on
empirical assumptions in carcinogenic risk
assessment. In particular, PBPK models
provide a basis for a more biologically
based approach to dose, route, and species
extrapolation. While physiologic modeling
thus provides a more rational approach to
risk assessment, there may be a number of
uncertainties associated with its use since a
moderately large number of parameters,
each subject to some degree of error, are
required for risk assessment applications.
The purpose of this article is to review
the collective experience to date in develop-
ing PBPK models for carcinogenic chemi-
cals, with a view to evaluating their role as
a tool for obtaining more accurate predic-
tions of carcinogenic risk through
improved tissue dosimetry. We begin with
a step-by-step overview of the process of
building a PBPK model, defined in terms
of mass-balance equations for individual
compartments included in the model
("Development of a PBPK Model").
Appropriate measures oftissue dose are dis-
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cussed in "Tissue Dosimetry." Because
PBPK models may involve in excess of20
or more parameters, we review recent
investigations designed to identify those
parameters to which predictions of tissue
dose are most sensitive ("Sensitivity
Analysis"). The use ofPBPK models devel-
oped to describe the fate of methylene
chloride, styrene, ethylene oxide, 1,4-diox-
ane, 1-nitropyrene, as well as polychlori-
nated biphenyls, dioxins, and furans is
reviewed in "Applications of PBPK
Modeling." Special considerations in the
application of PBPK models are discussed
in "Other Considerations in Applications
of PBPK Models," including the effects of
aging, topical adsorption in inhalation
studies, pregnancy, and exposure to com-
plex mixtures. The linkage between phar-
macokinetic models used for tissue
dosimetry and pharmacodynamic models
of carcinogenesis is explored in
"Pharmacodynamics."
Development of a
PBPK Model
A PBPK model envisages the body as being
comprised ofphysiologically similar com-
partments. Each compartment represents
an organ or tissue group, and linked to the
central blood compartment by arterial and
venous blood flow. The model is character-
ized by physiologic parameters such as tis-
sue volumes and blood flow rates,
biochemical parameters such as the parti-
tion coefficients, and kinetic parameters for
metabolism and removal. These parameters
are used to provide a mathematical descrip-
tion of the model using mass-balance
equations for individual compartments.
General Organ Compartment
Consider first the general organ shown in
Figure 1. A xenobiotic that has been taken
up by the body and entered the blood-
stream may enter the compartment
through the arterial blood and leave
through the venous blood. In certain com-
partments, the compound may enter or
leave the compartment directly by nonarte-
rial routes. For example, a compound
could be removed from the liver by metab-
olism or from the kidneys by excretion.
Compartment kinetics can be represented
by the mass-balance equation:
tC,I(t)=(Qi/UA)(Cb(t)-ViW)
+(I/ui)d at (t)-(I/ui)-zi(t). dt dt i
vi
QjVj QiA
Zi
Figure 1. Schematic diagram of a general organ com-
partment: Ci(t) = concentration of xenobiotic in tissue i
attime t; Q = blood flow rate; U =tissue volume; A(t)=
concentration of xenobiotic in arterial blood;Vi(t) = con-
centration of xenobiotic in venous blood;Yi(t) = amount
of xenobiotic directly entering compartment; Zj(t) =
amount of xenobiotic directly removed from compart-
ment.
Note that the concentration in the arte-
rial blood is the same in all compartments.
The allometric parameters such as tissue
volume and blood flow rate involved in
this equation are generally obtained by
referring to published reference values (5).
Many PBPK models regard tissue
uptake ofchemical to be flow limited (6).
It assumes that the venous blood from the
tissue is in equilibrium with chemical in
the tissue. This condition is related to the
partition coefficient between tissue and
blood. So
Vi(t)=Ci(0)/Pi) [2]
where Pi denotes the partition coefficient
between tissue and blood. The partition
coefficient represents the ratio ofthe con-
centration of the compound in the tissue
relative to that in blood under steady-state
conditions.
For some compounds like 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), the abil-
ity ofthe tissue to retain the compound is
limited by the availability ofspecific bind-
ing media such as protein. In this event, the
linear relationship in Equation 2 must be
replaced by a more complicated one allow-
ing for saturation ofprotein binding (7).
The term aYj(t)/at represents the rate
at which the compound enters the com-
partment directly. This can occur in blood
or skin at time to with intravenous or der-
mal exposure. Direct entry with a single
exposure can be represented by the Dirac
delta function:
Yi (t)3(t), [3]
where a(t) = 1 for t= to and is 0 otherwise.
Continuous infusion from time tj to t2 is
represented by a step function with
d-yi(t)=1 tl < t < t2
dti 0 otherwise. [4]
First-order absorption following a single
exposure at time t= 0 is represented by:
where kla > 0 represents the kinetic rate
coefficient for absorption.
dYi(t) =ekt
dt [5]
The term aZj(t)kJt represents the rate
of removal ofcompound directly from the
compartment. This includes the excretion
ofthe compound from the body and the
bioconversion ofthe substance into other
compounds by metabolism. Metabolism is
usually modeled using either linear kinetics
d atZi(t) =kiVi dt [6]
or saturable nonlinear kinetics
d Zi(t) =Vm.Vil(Km +V) dt ~~~~~~~~~[7]
Here ki is a first-order kinetic rate
coefficient that can be estimated from
metabolic studies. The parameter Vax is
the maximum rate of metabolism under
Michaelis-Menten kinetics, and K is an
equilibrium constant that is numerically
equal to the concentration ofthe substrate
when the rate ofmetabolism is one-halfof
Vnax. At low dose where the venous blood
concentration V. is less than Km, the
Michaelis-Menten Equation 7 can be
approximated by a linear process as in
Equation 6 with a rate coefficient of
V 1Km. At high doses, the Michaelis- maxm
Menten equation approximates a zero-
orderprocess with aYi(t)/lat V Vma.
The metabolism ofmethylene chloride
involves both the linear (glutathione-S-
transferase [GST]), pathway and the sat-
urable (mixed-function oxidases [MFO])
pathway (10). Therefore, both removal
processes (Equations 6 and 7) are required
in the PBPK model for this compound.
With benzene, the first-generation
metabolite (benzene oxide) is further
metabolized into several phenol conjugates,
phenyl mercapturic acid conjugates, and
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hydroquinone conjugates. The generation
of these secondary metabolites is consid-
ered as a separate process outside of the
original five-compartment PBPK model for
benzene (11).
Blood comparment
The mass-balance equation for the blood
compartment takes a slightly different form
from that in Equation 1 to satisfy the con-
servation of mass across all compartments.
Specifically it is expressed as
+Cb(t) = (1/Ub)Xi Vi(t)
-(Q,,lUb)Cb(t) +(1 Ub)-dtYb(t)
-(llUb) d Zb(t) [8]
where Qb=XiQi, withIidevoting the sum-
mation excluding the blood compartment.
For most compounds, the concentration
in arterial blood leaving the blood compart-
ment is the same as the blood concentration
within the compartment. However, for
TCDD, it is necessary to allow for binding
to blood proteins. This effectively reduces
the concentration in arterial blood flowing
into different compartments (7).
Blood-LungCompartment
For a volatile compound, the function of
the lung must be included to represent the
transfer ofthe compound between inhaled
and exhaled air. The compartmental dia-
gram in Figure 1 is then modified as shown
in Figure 2, and the mass-balance equation
in Equation 8 becomes:
dtCb(t) =(Qv/Ub)(Cinh(t)
-Cav(t))
+(1IUb)XiQiVi(t)
-(Q/Ub)Cb(t)
+('IlUb) d Yb(t)-(llUb)dtZb(t) [9]
where Qaiv is the alveolar ventilation rate,
C;fh is the concentration ofthe compound
in inhaled air, and Caiv is the concentration
of the compound in alveolar tissue. The
alveolar ventilation rate is easily obtained
by direct measurement. The concentration
ofthe compound in inhaled air and alveo-
lar tissue can be expressed as
Cifl(t) = Ca(t)
and as:
[10]
[11] Caip(t) =PCb(t)
respectively, where Ca(t) denotes concentra-
tion in air, and Pa is air-blood partition
coefficient.
A more complex representation ofthe
blood-lung compartment has also been used
in the study ofmethylene chloride to take
into account metabolism in the lung, which
is one ofmethylene chloride's target organs
(10). The model uses one compartment to
represent the exchange ofmethylene chlo-
ride between air and blood, and another to
represent metabolism.
Selection ofPhysiologicCompartments
The body can be divided into two broad
classes according to the value ofthe ratio
U1/Q. in Equation 1. This ratio represents
the period of time required to replace the
volume of blood present in the ith com-
partment. The first class includes richly
perfused tissues such as the liver and kid-
ney; the second includes poorly perfused
tissue such as skin and fat (13). Since
metabolism in the liver represents a special
function, it is usually considered as a sepa-
rate compartment. Since fat will have
much larger partition coefficient for
lipophilic compounds, it may be consid-
ered as a separate compartment when
studying fat-soluble substances. These con-
siderations suggest the use of a PBPK
model with the following five compart-
ments: blood, liver, richly perfused tissue,
poorly perfused tissue, and fat. For volatile
compounds, the blood compartment may
be replaced by a blood-lung compartment.
With some variations, this basic five-com-
partment model has been widely used in
PBPK modeling.
SolutionofaPBPKModel
Consider the five-compartment PBPK
model shown in Figure 3, in which the
compound enters the blood compartment
directly and is metabolized principally in
the liver. The dynamics ofthis system are
governed by the mass-balance equations
representing the function ofeach compart-
y
Qalv CI,h
EQjVj
Qalv calv
EQ A
z
Figure 2. Schematic diagram of the blood-lung com-
partment.
_S
.R
_,
B= blood
F = fat
S = slowly perfused
R = richly perfused
L= liver
Figure3. Schematic diagram of a five-compartment PBPK
model.
ment. Ifall of these equations are linear,
then their solution can be expressed in
closed form. More generally, the solution
of both linear and nonlinear models can
now be obtained using numeric methods.
Computer programs such as Advance
Continuous Simulation Language
(ACSL)(14) and SIMUSOLV (15)
specifically designed for this purpose are
both efficient and easy to use.
To illustrate the solution of a PBPK
model, consider the physiologic data in
Table 1 for Sprague-Dawley rats previously
reported by Leung et al. (7). Solutions to
the five-compartment PBPK model shown
in Figure 3 based on these values are illus-
trated in Figure 4 for the case ofa single iv
bolus injection ofthe test compound. The
concentrations in each ofthe five compart-
ments are shown in Figure 4Awhen there is
no removal and all partition coefficients are
equal to unity. In this case, the blood con-
centration is highest at the time ofinjection.
As the compound is distributed to other
compartments, the concentration in the
blood decreases. At steady state, the concen-
tration is the same in all compartments.
The richly perfused compartment has
the smallest flushing time U /Qr. Because
the blood is being replaced quicker in this
compartment than others, the concentra-
tion of the compound in the richly per-
fused compartment increases more rapidly
than in other compartments. The concen-
tration in this compartment reaches its
peak when the venous and arterial blood
Table 1. Physiologic parameters of a Sprague-Dawley
rat(7).
Volume,
Compartment liter
Blood 0.015
Richlyperfused 0.012
Liver 0.015
Fat 0.033
Slowlyperfused 0.213
Bloodflow,
liter/hr
5.75
2.93
1.44
0.29
1.09
Timeconstant,
hr
0.0026
0.0041
0.0104
0.1149
0.1952
Volume 102, Supplement 11, December 1994 39KREWSKIETAL.
Concentration A
I1-I
0 -| / blood
0-6 richly perfused
0-4- liver slowly perfused
0-2- l-" a
0 005 0o1 0-15 02 02
Time
Concentration B
2.
I.
0-8-
06
0-4-
0-2-
_ .
0 0-05 01 0-15
Time
0-2
Figure 4. (A) Concentration in different compartmer
with no removal: P,=, Pe=, Ps=, Pf =1; (B) Concentrati
in different compartments with no removal: P,=
Pt=3, Ps=5, Pf=10.
concentrations are equal. Since the conce
tration in the blood compartment contin
ally decreases because of distribution
other compartments, eventually the co
centration in the richly perfused compai
ment surpasses that of the arterial bloo
Consequently, the richly perfused compa
ment starts to release the compound ba
into the blood where it is transported
other compartments. Furthermore, sin
the richly perfused compartment is the fi
compartment whose venous blood conce
tration reaches that ofthe arterial blood,
peak concentration will exceed that
other compartments.
The compartment with the next sma
est flushing time is the liver, in which t
peak concentration is achieved after that
the richly perfused compartment. Bo
slowly perfused and fat compartments ha
large blood flushing times. Consequent
the concentration in these two compai
ments increases slowly. The peak veno
blood concentration occurs at a much la
time, and is smaller in amplitude. At stea
state, the concentration in all compai
ments reaches the same equilibrium level.
When different partition coefficients o
assigned to different compartments, t
chemical flushing time UEPi/Qj assun
the role of the blood flushing time. T
partition coefficients for blood and for
richly perfused tissues are generally compa-
rable, so that there is no change in the order
in which compartments achieve their peak
concentrations. However, the partition
coefficient for fat can be much larger than
that for slowly perfused tissue, so that the
peak concentration in fatty tissue could
occur at a much later time. The steady-state
5 concentration in different compartments
are proportional to their respective partition
coefficients, as shown in Figure 4B.
The same model was modified to
include saturable metabolism in the liver
with Km = 0.36 and V = 3.6 (in arbi- m ~~~max trary units of measurement). Different
doses 1, 10 and 100 are used to demon-
strate the effect of saturation of removal.
Figure 5 shows the concentration of the
compound in the liver compartment, plot-
ted on a semi-logarithmic scale. At the low-
est dose, the venous blood concentration in
liver is below K at all times, so that
removal follows linear kinetics. At the mid-
dle dose, the venous blood concentration
Mts in the liver is above Km near its peak. At
Jon this time, removal reaches its maximum
2, rate and cannot proceed at a faster rate. At
all other times, removal is essentially linear.
Because ofthis saturation effect, the differ-
ence between the liver concentration at the
n- low and middle dose is not consistent over
u- time. With saturation of removal at the
to highest dose, more of the compound is
)n- retained in the liver. The differences
rt- among the three curves are therefore largest
d. near their peaks.
Lrt-
ck Tissue Dosimetry
to Some measure of the level of reactive
ice metabolites reaching the target tissue
irst should provide a better dose metameter for
n- risk assessment purposes than the adminis-
its tered dose. However, consideration needs
in to be given to the most appropriate way to
express tissue dose.
dl-
the
Of Concentration
)th
ave
tly,
Lrt-
)us
Lter
dy
.rt-
are
the
nes
he
10*
01
0-01
0 002 004 006 0-08 0-I
Time
Figure 5. Liver concentration with saturable removal
(Vmax 3.6, Km = 0.36.
IntegratedTissue Dose
Andersen (16) used an integrated measure
of tissue dose given by the area under the
concentration-time curve (AUC) for either
the parent compound or its reactive
metabolites in the tissue concerned.
Specifically, the AUC for the parent com-
pound in blood is given by
AUCb= Jo Cb(t4dt. [12]
For metabolites formed in the liver, we have
AUCZ =(I/Ut)Jfo-dZ(t)dt [13]
which is simply the total amount of
metabolite formed divided by the volume
ofthe liver. The AUC in blood can be esti-
mated directly by taking blood samples at
frequent time intervals. However, this can-
not be done in most other compartments,
since tissue samples generally require
destructive invasive sampling. Once a
PBPK model has been developed, however,
it can be used to predict tissue doses in any
ofthe model compartments. Specific target
tissues, ifthey are known, may be incorpo-
rated into the model as separate compart-
ments.
For a linear PBPK model, the AUC of
the parent compound in blood can be
expressed as
AUCb = a(1/Ql+Ilk,) [14]
following administration ofa single iv dose
dofa xenobiotic. Note that this expression
involves only the blood flow rate Q, to the
liver and the rate of metabolism k, in the
liver. The AUCs of the parent compound
in other compartments are related to those
in blood. Specifically, it can be shown that
AUCG = PI(AUCb- dlQ4)
AUC = PAUCb r rb
AUC = PAUCb S S
AUCf= PfAUCb
AUCz = dlU,.
[15]
[16]
[17]
[18]
[19]
Because of the relationship in Equation 2
between the concentration in a tissue com-
partment and venous blood leaving the
compartment, the AUC for venous blood
is the same for all compartments.
For a volatile compound with the blood
compartment replaced by a blood/lung
compartment, we have
AUCb= d(1/QI + 1lk1)G [20]
where G= l/(l+Qa,P/l(I/ Q4+ 1/k,)). The
Environmental Health Perspectives
blood
richly perfused
liver
slowly perfused
fat
dose - 100
dose =
40PHYSIOLOGICAL MODELINGAND RISKASSESSMENT
same factor G is applied to all other inte-
grated doses given in Equations 15 to 19.
This is similar to the steady-state solution
for the metabolic clearance fraction given
by Bogen (17).
Equations 15 to 18 provide simple rela-
tionships between the AUC in blood and
other compartments. Since AUCb can be
determined directly from blood concentra-
tion measurements, these relationships
could be used to predict the AUC in other
compartments without constructing a
complete PBPK model. Note that
Equations 15 to 18 make no assumptions
about the number of compartments
included in the model, or the nature of
metabolic processes (linear or saturable).
In a linear system, the only parameters
which are important for the computation
of the integrated dose are the blood flow
rate to the liver Ql, the removal rate ofthe
compound in the liver kl, and the parti-
tion coefficient Pfor the specific compart-
ment. Other physiologic parameters such
as tissue volume do not enter into the cal-
culation. An increase in compartmental
volume will increase the blood flushing
time (as discussed previously) as well as
delay the occurrence of the peak concen-
tration and reduce amplitude. However,
the AUC in that compartment remains
unchanged.
The relative magnitudes of the AUCs
in different compartments are determined
solely by the partition coefficients. A
change in the volume or blood flow rate in
a compartment will only change the shape
of the concentration-time curve, not the
integrated tissue dose.
The integrated dose is dependent on
the blood flow rate into the liver compart-
ment. Because an increase in blood flow
into the liver will increase the supply ofthe
compound to liver tissue, and hence
increase removal. Since the blood concen-
tration declines monotonically following
administration of a single iv dose, an
increase in the rate of the change in the
liver concentration will decrease AUC,.
A compact solution for AUCbsimilar to
that in Equation 14 cannot be found for a
nonlinear PBPK model. However, the sim-
ple relationships given in Equations 15 to
18 remain valid (18). Equation 20 now
assumes the more complex form
fo(V,",C1/(PI +C,))dt
=d [20]
Here the integrand is the rate of metabo-
lism, and the integral on the left-hand side
is the total amount of metabolite pro-
duced. This equation simply reflects the
fact that the total amount ofthe metabolite
produced should equal to the amount of
the parent compound administered.
Sensitivity Analysis
From the systems analysis point ofview, a
PBPK model can be seen as a system where
the level ofexposure to a xenobiotic repre-
sents the input, and the dose ofthe reactive
metabolite reaching the target tissue repre-
sents the output. The output relates to the
input by means ofa PBPK system that typ-
ically involves 20 or more parameters.
Systems engineers often conduct analyses
to determine how sensitive the model out-
puts are to changes in the values of the
model parameters. Sensitivity analyses of
this type offer a means of estimating the
uncertainty in predictions of tissue doses
conferred by uncertainty in the PBPK
model parameters. Sensitivity analysis may
also identify critical parameters that con-
tribute most to the overall level of uncer-
tainty in model outputs.
The first analysis of the uncertainty in
PBPK model outputs was conducted by
Portier and Kaplan (19). These investiga-
tors studied the PBPK model developed by
Andersen et al. (10) for methylene chloride
(DCM), which includes a total of23 dis-
tinct parameters relating to tissue weights,
blood flow rates, partition coefficients, and
metabolic constants. Rather than focusing
directly on the metabolites of methylene
chloride reaching the lung and the liver,
Portier and Kaplan (19) used the PBPK
model predictions ofmetabolite concentra-
tions in these two tissues to estimate the
lifetime cancer risk due to exposure to
methylene chloride. In this analysis, an
essentially linear pharmacodynamic model
was used to estimate cancer risks, with tis-
sue doses expressed in terms of the area
under the concentration-time curve in
lung or liver for metabolites ofDCM pro-
duced by the glutathione-S-transferase
(GST) pathway.
Plausible ranges of uncertainty for the
PBPK model parameters were based on
published data when available; otherwise,
coefficients ofvariation ofthe parameters
were arbitrarily assigned values of 20 to
200%. Portier and Kaplan (19) reported
that the variability in the 10-6 RSD (the
dose estimated to increase the lifetime can-
cer risk by one in a million) was substan-
tially greater allowing for uncertainty in
the PBPK model parameters in comparison
with treating these parameters as known
constants. Specifically, the standard devia-
tion of the distribution of RSDs was
increased by a factor ofabout 10-fold.
Farrar et al. (20) conducted a similar
uncertainty analysis for perchloroethylene
using the PBPK model similar to that used
in modeling styrene by Ramsey et al. (21).
Because certain model parameters were not
independent of one another, multivariate
probability distributions were used to char-
acterize prior information on parameter
uncertainty. This study focused on three
measures of tissue dose, namely the areas
under the concentration-time curves for
TCE in the liver and arterial blood, and
the area under the concentration-time
curve for metabolites ofTCE in the liver.
In addition, the variability in the RSD
based on the induction of hepatocellular
carcinomas was also considered. Although
the results were generally supportive ofthe
findings ofPortier and Kaplan (19), these
investigators concluded that the choice of
an appropriate measure oftissue dose was
of relatively greater importance for cross
species extrapolation than uncertainty in
PBPK model parameters.
Subsequent investigations have also pro-
vided useful information on uncertainty
associated with predictions oftissue doses
based on PBPK models. Hattis et al. (22)
reported appreciable differences in predic-
tions ofthe metabolism ofperchloroethyl-
ene based on PBPK models constructed by
seven different groups of investigators.
Although there were some structural differ-
ences in the models used, the most impor-
tant factor appeared to be the data used to
calibrate metabolic parameters. Bois et al.
(23) noted that three independently devel-
oped PBPK models for benzene provided
noticeably different fits to the same data on
benzene metabolism. It was further shown
that acceptable fits to this data could be
obtained with a relatively wide range of
parameter values. Hetrick et al. (24) con-
ducted asensitivityanalysis ofPBPKmodels
developed for styrene, methylchloroform,
and methylene chloride. Predictions oftis-
sue doses were shown to be particularlysen-
sitive to the maximum rate of
(Michaelis-Menten) metabolism and
blood-air and blood-fat partition
coefficients. The degree ofsensitivity was
shown to depend on the dose ofthe parent
compound, the time at which tissue doses
were predicted, and the species for which
the PBPKmodel was developed.
Applications of
PBPK Modeling
In the examples discussed below the resolu-
tion ofmany of the mechanisms involved
in the uptake, distribution, metabolism
and persistence of chemicals in the body
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have been adequately resolved by the appli-
cation of physiologically based models.
Although some have been only partially
resolved, the process of building a PBPK
model often raises various questions that
need to be addressed to elucidate pharma-
cokinetic mechanisms.
Methylene Chloride
The PBPK model for methylene chloride
derives from a relatively simple model for
volatile compounds originally developed
for styrene (10,21). This perfusion-limited
model incorporated five principal compart-
ments: the lung, both as a compartment of
excretion and, in some applications, the
site ofuptake; the liver, as the principal site
ofmetabolism; richly perfused tissues, such
as the kidney, brain and heart; slowly per-
fused tissues, such as muscle and skin; and
fat, which could play an important role in
storage and redistribution. Partition
coefficients for blood and tissues were
determined by in vitrotechniques (25,26).
Metabolism of methylene chloride,
measured by in vitro and in vivo tech-
niques, was shown to proceed by two dis-
tinct pathways (26,27). One pathway
involved the mixed-function oxidases
(MFO) and the other was mediated by
cytosolic GST. The MFO former pathway
was found to be saturable in rats and mice
at inhalation exposures of greater than
about 200 ppm over a 6-hr period. The
GST pathway was not saturable at concen-
trations up to 10,000 ppm over the same
exposure period (26).
The delivered dose of the glutathione
conjugated to the target tissues in rats and
mice (liver and lung) and correlated better
with carcinogenic response than did either
the exposure dose or the products ofmetab-
olism by the mixed function oxidase path-
way. In vivo and in vitro data from exposed
humans and human tissues were used to
calculate various estimates ofcancer risk in
humans. A comparison ofthe physiologi-
cally based pharmacokinetic model risk
assessment data for liver tumors in humans
showed that it was 168 times less than that
calculated using the conventional U.S.
Environmental Protection Agency (U.S.
EPA) methodology, while the risk for lung
tumors was 143 times greater using the
U.S. EPAapproach (28,29).
Ethylene Oxide
Ethylene oxide (EtO) is used in the steriliza-
tion ofmedical devices and as a fungicide in
agriculture. It has also been identified as a
human metabolite ethylene, a common air
pollutant (30). In the evaluation ofethylene
oxide as a carcinogen (31,32), the active
carcinogenic species was considered to be
ethylene oxide per se with the formation
and elimination ofmetabolites representing
a detoxification process (29).
The distribution ofEtO was considered
to be uniform throughout the body
because of the similarity oftissue-blood
partition coefficients in different compart-
ments. It was also considered to be metab-
olized, principally by hydrolysis, to varying
degrees in all compartments (33).
Hydrolysis, without the intervention of
enzyme catalysts, was shown to be followed
by some degree of conjugation with glu-
tathione (34,35). In addition, EtO has
been shown to alkylate DNA and other
biologic macromolecules (including hemo-
globin) bydirect interaction (36,37).
The physiologic model used to fit
blood and tissue concentration data, was
similar to that used for methylene chloride
and styrene, except that the brain and
testes were isolated from the richly per-
fused tissue compartment since these have
been identified as target organs for EtO in
animal studies (38,39). Rate constants for
glutathione conjugation and DNA adduct
formation were estimated from studies
reported in the literature (40,41).
Data obtained in rats following iv
administration and inhalation exposure
allowed the simulation ofethylene oxide
concentrations in target tissues as well as
and the concentration ofDNA and hemo-
globin adducts. Experimental data follow-
ing the iv administration of up to 100
mg/kg of EtO or after exposure to inhala-
tion exposures to 1200 ppm for 6 hr did
not appear to demonstrate biochemical
thresholds; whole body elimination ofeth-
ylene oxide appeared to follow first-order
kinetic process. However, this analysis
facilitated the identification and characteri-
zation of the hydrolysis of EtO, glu-
tathione conjugation, exhalation, and
DNA or hemoglobin binding. These latter
processes were affected by saturation of
elimination pathways at high-exposure
concentrations where the whole body elim-
ination continued to follow first-order
kinetics (33). Information on the meta-
bolic capacity of human tissues for the
hydrolysis and glutathione conjugation of
ethylene oxide would greatly facilitate the
extrapolation of animal cancer risk esti-
mates to humans.
1,4-Dioxane
1,4-Dioxane has been used for decades as
an industrial solvent. Aside from inducing
hepatic and renal effects it has also been
shown to induce liver tumors in rodents
and to induce nasal carcinomas in rats
(42-44). Young et al. (45) showed that
the metabolism of 1,4-dioxane was sat-
urable at high doses.
Two recent reports on the application of
physiologically based pharmacokinetics of
1,4-dioxane (8,46) incorporated the kinetic
constants for the formation ofthe principal
metabolite (P-hydroxy ethylacetic acid). The
model accommodated the administration of
1,4-dioxane by the iv, inhalation, and oral
routes and allowed the calculation ofthe sur-
rogate delivered doses to various organs, par-
ticularly the liver. Metabolic thresholds were
observed at water concentrations ofgreater
than 1% administered by the oral route and
at atmospheric concentrations ofgreater
than 300 ppm inhaled continuously (8).
These investigators suggested that unless the
physiologic and metabolic differences
between humans and rats were corrected for,
human cancer risk based on traditional risk
assessment methods applied to the adminis-
tered dosewould beoverestimated.
1-Nitropyrene
1-Nitropyrene, a nitrated polycyclic aro-
matic hydrocarbon, has been detected in
diesel exhaust emissions, coal combustion
products, and photocopier toners (47-49).
1-Nitropyrene is closely related to the class
of compounds known as polycyclic aro-
matic hydrocarbons, many ofwhich are
known carcinogens. The systemic uptake,
metabolism and excretion of 1-nitropyrene
has been shown to be very rapid with wide
distribution to body tissues (50).
1-Nitropyrene is a potent bacterial and
mammalian mutagen, and induces lung
tumors in mice and mammary tumors in
rats following subcutaneous injection
(51-53). Tumors were also found at the
injection site.
Medinsky et al. (54) developed a
PBPK model for 1-nitropyrene incorporat-
ing the principal organs to which 1-
nitropyrene was distributed, metabolized
and bound (namely the upper respiratory
tract, lung, liver, and kidney). This model
provided a good description of the clear-
ance ofmetabolites via the bile and feces as
well as through urine. Partition coefficients
for the lung, liver and kidneys relative to
blood were found to be close to unity,
indicating that consideration ofblood flow
alone is sufficient to describe the clearance
of 1-nitropyrene from these tissues. This
model appeared to provide a good descrip-
tion of the doses of 1-nitropyrene and its
metabolites to target tissues, as well as their
temporal relationship postexposure.
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Polychlorinated Biphenyls,
Dioxins, and Furans
These classes ofchemicals represent a major
group ofubiquitous and persistent environ-
mental pollutants that have been a cause of
great concern for the past several decades
(55). While the mechanisms involved in the
toxicity ofthese groups ofchemicals are still
under investigation, immune alterations and
decreased specific antibody response (56,57)
have been noted for the chlorinated
biphenyls and 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) (58,59). The polychlori-
nated biphenyls tend to act as
hepatocarcinogens (44,60) induces liver
tumors in rats and is cocarcinogenic (61,62).
The toxicity of the dioxins and furans
differs markedly among species (63,64) as
does their pharmacokinetics and disposi-
tion (65,66). The chlorinated dibenzodi-
oxins and dibenzofurans accumulate in the
liver and adipose tissue, although there are
notable species differences in their relative
distribution to these tissues (67). This may
be due in part to binding at different sites,
such as the Ah locus, in responsive and
nonresponsive different species (68-70).
The PBPK models proposed for
polychlorinated biphenyls (12,71), 2,3,7,8-
tetrachlorodibenzo-p-dioxin and 2,3,7,8-
tetrachlorodibenzofurans (65,66,72,73) are
all rather similar. They generally involve five
or six compartments, consisting of the
blood, slowly perfused tissues, and richly
perfused tissues with separate compartments
for the principal target tissues: fat and liver.
For hexachlorobiphenyl, the model was
able to describe blood level data ade-
quately following the administration of a
single iv dose in the rat (12). Since this
compound is excreted very slowly, blood
concentrations were followed for 43 days
postdosing. Growth, particularly ofthe fat
compartment, was incorporated into the
model. The rate of conversion to, and
excretion of, the glucuronide conjugate via
the bile was taken into account.
Enterohepatic recycling was considered to
be important. The authors expressed the
opinion that the variables in the model
had been adequately assessed and that
species and route variations could be
accommodated to describe the delivered
dose to specific target tissues.
For the polychlorinated dibenzodioxins
and dibenzofurans, bile rather than urine
was considered to be the major route of
excretion. The liver is a major site of toxic
action of these agents. Liver-blood parti-
tion coefficients were very large, ranging
between 30 and 130 for the various rodent
and primate species considered.
Microsomal enzyme induction and binding
to the Ah receptor sites were accommo-
dated in the PBPK model. Since the aryl-
hydrocarbon hydroxylase complex has been
implicated in the carcinogenic mecha-
nism(s) for these compounds, it has been
suggested that the PBPK model could be
useful for cancer risk assessment
(7,65,72-74).
Other Considerations in
Applications of PBPK Models
The development of a PBPK model for a
particular compound may require special
consideration of factors other than those
involved in the applications described in the
previous section. One of the benefits of
building a PBPK model is increased under-
standing ofthe pharmacokinetic processes
involved in the distribution and elimination
ofxenobiotics. The examples that follow
illustrate the need for enhanced PBPK mod-
eling to accommodate the effects ofgrowth
and aging, topical adsorption, pregnancy,
and competitive multiple metabolites.
AnimalAgingandBodyGrowth
In the studies of the pharmacokinetics of
polychlorinated biphenyls discussed earlier
(12,71), it was found that hexachloro-
biphenyl is excreted very slowly by the rat.
At 6 weeks, postdosing, over 80% ofthe iv
dose was retained, and the fraction that was
excreted in the urine and feces comprised
mainly of metabolites. Over this time
period the rats, originally weighing
between 250 and 300 g, gained appreciable
body weight. Since fat increases propor-
tional to total body weight when the ani-
mal grows, hexachlorobiphyl in poorly
perfused fat tissue became increasingly
diluted during the experiment. Thus, fat
concentrations beyond 8 days postdosing
were not well predicted without the incor-
poration of an adjustment for the increase
in the volume ofthe fat compartment as a
function ofage.
A similar circumstance arose in
attempts to fit data obtained from pharma-
cokinetic and tissue disposition studies of
methyl chloroform in young and old
rodents (75,76). To fit the data obtained
from old (18.5 months) rats, it was neces-
sary to increase the size ofthe fat compart-
ment from 7% (for young, 1- to 3-
month-old rats) to 18% of their body
weight. The concentration ofmethylchlo-
roform in body fat was 20 to 100 times
greater than that in any other tissue. Thus
the model predicted that the increased size
of the fat compartment in older animals
would increase the amount taken up. The
model also predicted that methyl chloro-
form would be more slowly released in
younger animals than in older animals. The
same integrated model was found to be
applicable to data derived from iv adminis-
tration, inhalation, bolus gavage, and
administration in drinking water, as well as
data obtained with repeated doses (8).
TopicalAdsorption in
Inhalation Studies
Inhalation studies ofvolatile chemicals have
usually carried out by placing the whole
animals in a carefully controlled exposure
chamber. In the closed chamber technique
(77,78) inferences about the kinetics of
uptake and disposition ofvolatile chemicals
are made by monitoring the change in
chamber concentration with time.
In studying the kinetics of chlorinated
ethane in rats, Gargas and Anderson (79),
encountered a high loss (78%/hr) ofethanes
containing three or more chlorine atoms
from empty chambers. This turned out to be
primarily due to adsorption to carbon diox-
ide adsorbents and to the inner chamber sur-
face. While these effects could be measured
and satisfactorily incorporated into the
PBPK model, the concentration of 1,1,2,2-
tetrachloroethane, in the chamber immedi-
atelyfollowing exposure, was underestimated
bynearlyan orderofmagnitude.
Since the excess chamber concentration
could be accounted for only as an additional
amount carried to the chamber passively by
the animal, it was assumed that tetrachloro-
ethane was adsorbed extensively to the fur
of the animals. This hypothesis was
confirmed by exposing rats to 350 ppm of
tetrachloroethane for 6 hr in an exposure
chamber. The animals were then given a
lethal dose of sodium pentobarbital and
placed singly in an exhaled breath chamber
with the chamber atmosphere monitored
for tetrachloroethane. Since the animals
were not breathing, it was assumed that the
atmospheric concentrations of tetrachloro-
ethane could only have been derived from
the desorption ofthe chemical from the fur
ofthe animal. This experiment allowed the
derivation of the amount of the chemical
adsorbed on the fur and a first-order rate
coefficient was determined for desorption
from the fur. When the fur adsorption/des-
orption data was used in conjunction with
exhaled breath analysis, the PBPKprovided
an adequate fit ofthe live animal data.
Pregnancy,Lacttion, andNursing
Many changes occur during pregnancy that
can have a significant impact on the toxico-
dynamics of a particular chemical. For
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example, the changes in body weight, total
body water, plasma proteins, body fat, and
cardiac output will alter the distribution of
manyxenobiotics (80-82).
PBPK models have been used to
describe the kinetics and disposition ofthe
drugs tetracyline, morphine, and metha-
done (83-85). Two recent reports
described the pharmacokinetics and dispo-
sition oftrichloroethylene and its principal
metabolite, trichloroacetic acid, in the preg-
nant rat as well as the lactating rat and
nursing pup. A PBPK model consisting of
eight compartments for trichloroethylene in
the pregnant rat and nine compartments
for trichloroacetic acid was used (86). Both
models accommodated multiple routes of
exposure and repeated dosing. The model
provided for a variable litter size 1 to 12
pups per rat as well as placental growth.
Values of the maximum rate of meta-
bolic removal velocity (1max) in naive and
pregnant rats were 10.98 and 9.18
mg/kg/hr, respectively. This reduction is
significant, and has been related to a
decrease in the cytochrome P450
monooxygenase activity due to altered
steroid hormones. A high substrate affinity
was demonstrated. Although the value of
the Michaelis constant (K) was low (0.25
mg/1), it was similar in both groups ofrats.
Fetal exposure to trichloroethylene was
estimated to range from 67 to 76% of the
maternal exposure; fetal exposure to the
trichloroacetic acid metabolite was 63 to
64% ofthat ofthe dam.
The model-fitted data obtained after
exposure by the inhalation, oral gavage, or
by drinking water. Other kinetic parame-
ters predicted by the model (such as the
relative volumes ofdistribution, the peak
blood concentration following oral gavage,
fetal concentrations following inhalation
exposure, absorption, and elimination
rates) agreed well with previous data
reported in the literature. These results
demonstrated that fetal exposure to both
the parent compound and its principal
metabolite was significantly elevated in
relation to the maternal exposure.
Fisher et al. (87) examined the transfer
of trichloroethylene and trichloroacetic
acid to nursing pups from lactating dams
exposed to trichloroethylene by inhalation
of 610 ppm, 4 hr/day, 5 days/week from
days 3 to 14 oflactation. A further study
involved exposure of the lactating dam to
333 mg/ml oftrichloroethylene in drink-
ing water from days 3 to 21 oflactation.
The exposure ofthe pups to trichloroethyl-
ene was solely from ingested maternal
milk; however, their exposure to
trichloroacetic acid derived from maternal
milk and from metabolism of ingested
trichloroethylene. The model provided for
different values during lactation for com-
partmental volumes, blood flows, and milk
yield obtained from the published litera-
ture. Metabolic and other kinetic parame-
ters were determined experimentally.
The values of Vmax = 9.26 mg/kg/hr in
the lactating rat was similar to that in the
pregnant rat. However, the value of Vma =
12.94 mg/kg/hr obtained for male and
female pups indicated that the ability of
the pups to metabolize trichloroethylene
was greater than that of the adult. The
plasma half-life (16.5 hr) oftrichloroacetic
acid in the pups was also substantially
greater than that ofthe mature rat. Unlike
most other physiologic distribution
processes which are flow limited, the distri-
bution oftrichloroacetic acid to mammary
tissue is diffusion limited. The exposure of
the pups to trichloroethylene from mater-
nal milk was small, representing only about
2% of the exposure of the dam. Pu.p
plasma levels of trichloroacetic acid; how-
ever, were as high as 30 and 15% of the
maternal exposure for drinking water and
inhalation exposures, respectively.
The interaction between two or more
chemicals is a very complex phenomenon
involving chemical interactions prior to
absorption, competition for a common
metabolic pathway, and competition for
sites of toxic action (88). Each of these
processes could be a consequence ofother
complex mechanisms that have seldom
been defined completely.
One example, in which PBPK modeling
has been used to describe the quantitative
interaction between two compounds
metabolized by the same microsomal oxida-
tion pathway is that of trichloroethylene
and 1,1-dichloroethylene (89). 1,1-
Dichloroethylene was shown to induce
acute hepatoxicity as a consequence the
reactivity oftheir metabolic products. The
metabolic pathway was the same for both
compounds, and there was high-affinity
substrate binding which was saturable (90).
Coexposure ofrats to 1,1-dichloroethylene
and vinyl chloride dramatically reduced the
hepatoxicity ofthe former (91).
A PBPK model was developed, assum-
ing competitive inhibition by both com-
pounds, to estimate the hepatoxicity of
1,1-dichloroethylene in the absence and
presence of trichloroethylene. Elevated
liver enzymes provided a pharmacody-
namic index of hepatotoxicity. In rats
exposed to 0, 200, 300, and 400 ppm of
dichloroethylene alone, it was observed
that the serum glutamic oxaloacetic
transaminase (SGOT) enzyme level
increased dramatically at exposures above
100 ppm. When animals were exposed to
300, 713, and 1718 ppm of 1,1-dichloro-
ethylene and 500 ppm oftrichloroethyl-
ene, the SGOT elevation was significantly
reduced. This behavior was consistent with
purely competitive inhibition with binding
constants of0.25 mg/l fortrichloroethylene
and 0.10 mg/l for 1,1-dichloroethylene. It
was evident that 1,1-dichloroethylene is a
slightly better substrate for microsomal oxi-
dation than trichloroethylene. The model
was able to predict the combined pharma-
codynamic effects of these two substrates
when coadministered in anyproportion.
Pharmacodynamics
Chemical carcinogenesis is a complex
process involving a number ofsteps, which
may include biotransformation of the par-
ent compound to its reactive metabolites,
DNA damage, mutation, proliferation of
mutated cells, progression to a malignant
state, and growth ofmalignant tissue to
overt tumors (66,92). The two-stage clonal
expansion model ofcarcinogenesis, origi-
nallydeveloped byMoolgavkar and Venzon
(93) and Moolgavkar and Knudson (94)
provides a convenient framework for
describing the process ofcarcinogenesis.
The model is based on the premise that
two critical mutations are required to con-
vert a normal stem cell to a malignant can-
cer cell; the effects of cell kinetics are
reflected in the birth and death rates of
stem cells as well as initiated cells which
have sustained the first mutation.
The dose of the proximate carcinogen
to the target tissue can impact the process
of neoplastic transformation in several
ways. The probability ofeither a first- or
second-stage mutation can be increased by
direct alkylation ofDNA at the time ofcell
division. Mitogenic compounds which
increase the rate at which stem cells divide
can also increase the mutation frequency
by increasing the opportunity for either
spontaneous or induced mutation. Once a
genetic lesion induced in a stem cell has
been fixed byreplication, promoting agents
may augment the size of the iniated cell
population by selective clonal expansion of
initiated cells. Increasing the pool of initi-
ated cells increases the number of cells at
risk ofsustaining the second critical muta-
tion, which completes the process of neo-
plastic conversion. This two-stage model of
carcinogenesis is no doubt an over-
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simplification of the process of neoplastic
transformation. Nonetheless, it does
embody critical factors such as mutation,
tissue growth, and cell kinetics involved in
carcinogenesis, and has proven useful in
modeling dose-response relationships
observed in toxicologic and epidemiologic
studies (1).
An important consideration in such
applications is the manner in which dose in
incorporated into the modeling process. In
most applications, the external level of
exposure to the host has been used in pre-
dicting cancer risk. The use ofthe external
level of exposure in dose-response model-
ing can lead to biases in predictions oflow-
dose cancer risks when the relationship
between the administered dose level and
the dose ofthe reactive metabolite reaching
the target tissue is nonlinear (95).
Physiologic models offer an approach to
tissue dosimetry which can be used to
avoid such biases.
PBPK models permit calculation ofvar-
ious measures of tissue dose. With a given
chemical carcinogen, the mechanisms of
interaction between dose and tissue con-
stituents and the mechanisms by which
these interactions lead to cancer will deter-
mine the proper measure oftissue dose for
risk assessment calculations. Within the
framework of the two-stage model,
increases in either mutation rates or growth
rates of normal or intermediate cells can
lead to increased cancer risk. It follows that
the interaction of the toxicant with target
tissue must have cellular consequences that
are eventually reflected in alterations in the
rates ofone or more ofthese processes.
Mechanistic information has been used
to suggest a very broad brush classification
of chemical carcinogens (92). Genotoxic
carcinogens interact directly with DNA
bases to form promutagenic adducts which
alter mutational probability during cell divi-
sion. Nongenotoxic carcinogens do not
interact directly with DNA; rather, they
alter cell division rates. These alterations can
either be due to direct mitogenic stimula-
tion ofthe tissue or indirectly as a reparative
process following tissue cytotoxicity.
Because all carcinogens interact with cells
leading to formation ofgenotypically altered
cells and must therefor have some genotoxic
sequelae, the terms DNA reactive and non-
DNA reactive have also been suggested as a
more appropriate than genotoxic/nongeno-
toxic. Another proposal is the differentiation
between genotoxic and operationally
nongenotoxic carcinogens. In general DNA
reactive carcinogens are initiators and the
non-DNA reactive chemicals are promoters.
The mechanism oftoxicant-tissue interac-
tion specifies the linkage between dosimetry
ofthese individual carcinogens and the rates
ofmutation or ofproliferation ofnormal and
altered cells involved in tumor formation.
The linkage between tissue dose and these
cellular parameters for three broad classes of
chemical carcinogens is examined below.
DNAReactive Chemicals
Certain electrophiles react with nudeophilic
sites on DNA bases to form promutagenic
adducts. Chemicals such as ethylene oxide,
propylene oxide, dimethylmethylsulfonate,
and bis-chloronitrosourea react directly with
these bases (96,97). Other chemicals such as
nitrosamines, vinyl chloride, and aflatoxins
have to be metabolized in the body to form
reactive electrophiles (96). In either case,
tumor formation is believed to be associated
with changes in mutation probabilities
related to the production and persistence of
adducts. The adducts are generally expected
to be formed by second-order reactions and
removed by saturable repair enzymes. For a
chemical like ethylene oxide (EtO), the
equation for the rate of change in the
amount oftissue adducts overtime tis (33):
Va[DNA-EtO]k/t=k[EtO] [DNA]V'ax
-VI'-[DNA-EtO]/(KA +[DNA-EtO])
[22]
Here, [EtO], [DNA], and [DNA-EtO]
denotes the concentration of EtO, DNA,
and DNA-EtO adducts in the target tissue
with volume V. The parameter k represents
the second-order rate constant at which
adducts are formed, with Vmax and K
mx m
denoting the Michaelis-Menten parame-
ters for (saturable) enzymatic repair.
With this model, [DNA-EtO] can be
used as a surrogate for increases in probabil-
ity of mutation in each cell division event.
Highly reactive chemicals will form several
different adducts and the mutational
efficacy will vary for each ofthese individ-
ual adducts. However, if all processes are
linear, the increased mutational rates would
still be expected to be linearly related to the
integrated tissue exposure to EtO. In this
case, the cumulative exposure ofthe target
tissue to the critical reactive metabolite may
be used as a measure of tissue dose. Other
factors need to be considered in interspecies
extrapolation. For example, it is unclear
whether risk across species for DNA reac-
tive chemicals should be normalized based
on integrated daily dose or on integrated
lifetime dose. In either case, the tissue dose
metameter is the integrated tissue dose of
DNA reactive electrophile integrated over
an appropriate period of the animal or
human life-span.
Non-DNAReactive Cytoxic Chemicals
With non-DNA reactive chemicals, the ini-
tial cellular interactions are frequently asso-
ciated with accumulation ofsufficient doses
ofhighly reactive species to cause cell death.
The parent compound may be reactive, as
with formaldehyde in the nasal mucosa or
ethyl acrylate and ethylene dichloride in
forestomach (97,98). In other cases, the
chemical is converted to reactive metabolites
in the target tissues: chloroform, carbon
tetrachloride, and vinylidene chloride kill
hepatocytes only after metabolism to phos-
gene, trichloromethyl free radical, and
chloroacetylchloride, respectively (99-101).
The mechanisms of toxicant-target tissue
interaction vary depending on the chemical
nature ofthe reactive intermediate. Some
reactive chemicals form long-lived stable
adducts with cellular proteins and lipids.
Examples include carbon tetrachloride and
acetaminophen (99,102). The depletion of
critical tissue macromolecules below critical
levels then leads to cell death. For carbon
tetrachloride (CC14), a reactive trichloro-
methyl free radical ( CCI3) covalently binds
to macromolecules. The two equations
relating tissue-macromolecule [tissue-MM]
concentrations include terms for MM syn-
thesis (ko), MM degradation (kl), loss of
MM due to a second-order reaction with
reactive chemical (k2), accumulation ofthe
tissue-CCI3 adducts from the second-order
reaction, and degradation of the adducts
(3):
a[Tissue-MM]/at=K,-kl[Tissue-MM]
-k2[ CCl3] [Tissue-MM] [23]
and
a[Tissue-CCl3]/dt =
k2[ CCl3] [Tissue-MM]-k3[Tissue-CCl3]
[24]
The concentration offree radicals should be
related to the reaction rate divided bythe tis-
sue volume (10). In this example, biologic
factors such as the MM synthesis rate and
degradation rate constant ofadducted pro-
tein and lipid are important factors in inter-
species extrapolation. Cell death is expected
to be associated with reduction of tissue
MM below critical levels for some period of
time. A PBPK model ofCCI4 has been used
to estimate tissue burdens ofbound reactive
metabolite in rats (103), although it has not
yet been applied in a risk assessment calcula-
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tion. Cis-platin, a cancer chemotherapeutic
agent, forms protein adducts which have a
cell half-life similar to the cell half-life esti-
mated for the CC13 adducts from carbon
tetrachloride. Farris et al. (104) have devel-
oped a detailed PBPK model of cis-platin
that describes adducts with both low molec-
ular weight and high molecular weight pep-
tide constituents in cells. Unlike CHCl3
which does not react appreciablywith DNA,
cis-platin cytotoxicity is believed to be related
causally to its cross-linking with DNA that
interferes with cell replication.
With CHC13, a PBPK model has been
developed to estimate cell killing under var-
ious exposure conditions in rats and mice
(105). CHC13 is metabolized to short-lived
intermediates, phosgene and hydrochloric
acid, which are highly irritant, but whose
adducts are not persistent (106).
Cell death was more closely associated
with high rates of metabolism over rela-
tively short times then to persistence of
macromolecular adducts (105,107). An
empirical approach was taken to describe
the relationship between the rate ofdeath
of normal hepatocytes (-4JNhlat) and the
rate ofmetabolism per unit volume of tis-
sue (aAmetlat)/V). The rate of loss of
hepatocytes was modeled with a rate con-
stant for cell death (Kdeath), the number of
viable hepatocytes at any time (Nh), and a
distribution of sensitivities to cell killing
(SENS) that was based on the rate of
metabolism per unit tissue volume:
a(Nh)Iat=-Kdeath(SEN5)(Nh)- [25]
The sensitivity distribution described
the proportion ofcells at risk at any rate of
chloroform metabolism in the cell and was
derived empirically from appropriate
experiments. In the absence ofchronic tis-
sue injury, cell replication should restore
the tissue to normal functional status. The
cell replication rate should mirror the
death rate with some delay. The replication
rate affects the overall mutation rate, which
corresponds to the product of mutation
probability per cell division and the rate of
cell division.
Many chemicals will resist such simple
classification, and demonstrate characteris-
tics shared by multiple categories.
Nitrosamines are highly mutagenic, but are
also cytolethal at high doses. These chemi-
cals alter both mutational and replicative
processes in cells in the target tissues
(108). The mutational efficacy persists
even at doses below which there is little cell
killing. Formaldehyde is cytolethal and
produces DNA-formaldehyde-protein
cross-links which probably have mutagenic
potential (109). The exposure response
relationships for both processes are nonlin-
ear with similar shapes. The mutation rate
for chemicals with cytotoxic and DNA
reactive characteristics should be related to
the product of replication rate times the
level ofcross-links; the increases in replica-
tion rate should affect other cell growth
parameters as well (110).
Non-DNAReactiveMitogenic
Chemicals
It is difficult to define the action of this
diverse class of carcinogens by a single
mechanism. These compounds appear to
promote tumor development primarily by
increasing cell replication in the two-stage
cancer model, and frequently by selective
enhancement ofreplication in preneoplas-
tic instead ofnormal tissue. Many ofthese
chemicals act via receptor molecules to
modulate expression ofprotein growth fac-
tors. Examples include dioxin, dioxinlike
polyhalogenated biphenyls and dibenzofu-
rans, peroxisomal proliferators, phenobar-
bital, and phenobarbitallike PCBs, as well
as various hormones and hormone-analogs.
The relevant measure ofbiologic dose lead-
ing to cell replication is the alteration in
concentration ofprotein-growth regulatory
products. The relevant measure of tissue
dose ofchemical must be related to inter-
actions between the chemical and the
receptor molecules responsible for regulat-
ing expression ofthese growth factors.
PBPK models for dioxin have
attempted to link dioxin tissue concentra-
tions, receptor action, and expression of
particular genes. To date, the models
account for expression of certain metabo-
lizing proteins, cytochrome P4501A1
(CYPlA1) an.d cytochrome P4501A2
(CYP1A2), but not for induction of
specific sets of growth factors. Dioxin
interacts with a cytosolic protein, the Ah
receptor, and the dioxin-receptor complex
translocates to the nucleus and, together
with at least one other protein factor, binds
to specific sites on DNA to modulate tran-
scription ofvarious genes (59,111). Several
receptor-based models linking tissue dioxin
and gene regulation have been described.
Initially, induction was calculated by esti-
mating the fractional occupancy ofthe Ah
receptor, as determined based on an Ah
receptor-dioxin binding constant, and the
tissue concentration of dioxin and Ah
receptor (46,112). More recently, this
induction model has been extended in an
attempt to account for ternary interactions
involving the binding of the dioxin-Ah
receptor complex to sites on DNA and the
possibility of cooperative interactions
among multiple DNA binding sites for this
complex in regulatory regions ofspecific
genes (112). The relationships modeled
include the binding of dioxin and Ah
receptor, cooperative binding ofthe recep-
tor-dioxin complex to DNA sites, and the
increased synthesis rate of protein conse-
quent to the alterations in gene transcrip-
tion. The two relevant relationships
become
[Dioxin-Ah] = [Dioxin][Ah receptor]/Kb
[26]
and
a[CYPlA1]k)t=K%+K ax[Dioxin-Ah]n/
([Dioxin-Ah]n+K7)-K [CYPlAl]. [27]
Here, Kb is the dioxin-Ah receptor dis-
sociation constant, Ko is the basal synthesis
rate ofCYPlAI, K is the fully induced max
CYPlAl synthesis rate, n is a Hill
coefficient interpreted as reflecting the
cooperative binding of the Ah receptor-
dioxin complex to regulatory regions of
DNA, Kdis the dissociation constant for
the DNA-dioxin-Ah complex, and Kj is
the degradation rate constant for the
CYPlAI under normal conditions. To be
of use in risk assessment, these models will
ultimately have to predict the regulation of
sets of growth regulatory genes in an
attempt to model the proliferative responses
directly. In the interim, the induction of
specific gene products, such as CYPlAI
and CYP1A2, can be used to develop corre-
lations with carcinogenic sequelae ofthese
promoters, bearing in mind that there is no
reason to expect a causal relationship
between these cytochrome activities and
tumorformation.
Summary and Conclusions
In this article, we have reviewed the devel-
opment and application of PBPK models
as a tool for estimating the dose ofreactive
metabolites ofchemical carcinogens reach-
ing target tissues. In general terms, PBPK
models envisage the body as being com-
prised as a small number of relatively
homogeneous physiologic compartments.
Such models are characterized mathemati-
cally by a system of mass-balance equa-
tions that can be readily solved using
modern computer software to obtain pre-
dictions of tissues doses. However, the
development and applications of a PBPK
model is not a trivial undertaking.
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Information on all of the allometric, bio-
chemical, and pharmacokinetic parameters
involved in the model must be developed,
and the model validated and refined by
appropriate experimentation. This process
can generate significant insight into the
uptake, distribution, metabolism, and
elimination of xenobiotics suspected of
increasing cancer risk.
From the risk assessment point ofview,
the primary goal of PBPK modeling is to
obtain more accurate estimates of cancer
risk through the use ofmore accurate mea-
sures oftissue dose. While the use ofmore
relevant measures of dose is likely lead to
progress towards this objective, the uncer-
tainty associated with predictions oftissue
dose must not be overlooked. This uncer-
tainty can be evaluated by considering the
precision associated with each ofthe model
parameters, and by identifying those para-
meters to which predictions of tissue dose
are most sensitive.
Complete, quantitative biologically
motivated models for carcinogenic risk
assessment must ultimately include several
components: a PBPK description for tissue
dosimetry, a linking model specifying the
mechanism by which tissue dose interacts
with cell constituents to produce alterations
in cell growth rates or mutation probabili-
ties during replication, and the impact of
alterations in these cellular events on tumor
promotion. Significant progress is evident
in development of PBPK models and in
investigating model sensitivity and the
impact ofparameter variability on risk cal-
culations (19,23,113,114). The two-stage
model is a promising quantitative descrip-
tion of the relationship between cellular
events and cancer which can be expanded
as new information on the obligate muta-
tional events in chemical carcinogenesis for
specific carcinogens becomes known in
more detail (93,115,116). The greatest
challenge today is the further elaboration of
these linkage processes that are important
in transducing chemical interactions into
direct biologic consequences. Perhaps the
most tangible reward expected from
improved quantitative linking models is the
more precise definition of the measure of
tissue dose and the possibility of better
definition of the manner in which these
measures of tissue dose should be normal-
ized across species for various mechanisms
ofaction to support informed interspecies
extrapolations.
The work required to develop these
comprehensive, biologically motivated risk
assessment models including their valida-
tion with specific experiments under long-
term chronic exposure conditions is
expected to be costly and time-consuming.
Clearly, it is impossible to create these
models for every chemical. A more reason-
able, cost-effective strategy may be to invest
in models for a limited number ofchemi-
cals with well-defined mechanisms ofaction
in order to create prototype risk assessment
approaches for generic classes ofchemicals
ofwidespread interest. With these proto-
type chemicals, model development early
on in the process of toxicity testing can
guide subsequent experimental design for
validating, refuting, or refining current
modeling methodologies. These linking
models are now in their formative stages,
and more work will be required to improve
the biologic basis of these descriptions and
test various assumptions. Their very exis-
tence, though, will help refine and focus
succeeding research efforts and improve the
likelihood that research will find more fruit-
ful the process of quantitative risk assess-
ment for chemical carcinogens.
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